Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Affimed Ord Shs (NQ: AFMD )

5.260 +0.025 (+0.48%)
Streaming Delayed Price Updated: 10:22 AM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Affimed Ord Shs

< Previous 1 2 3 4 Next >
6 Blue-Chip Stocks to Sell Now
This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
Monday's session saw 84 companies set new 52-week lows. 
Via Benzinga
Affimed: Q1 Earnings Insights
Affimed (NASDAQ:AFMD) reported its Q1 earnings results on Wednesday, June 1, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Affimed Q4 Earnings
  Affimed (NASDAQ:AFMD) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Affimed Q3 Earnings
Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For June 1, 2022
Companies Reporting Before The Bell • Affimed (NASDAQ:AFMD) is projected to report quarterly loss at $0.19 per share on revenue of $10.05 million. 
Via Benzinga
Earnings Preview: Affimed
Affimed (NASDAQ:AFMD) is set to give its latest quarterly earnings report on Wednesday, 2022-06-01. Here's what investors need to know before the announcement. Analysts estimate that Affimed will... 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Affimed Touts Encouraging Patient Responses For Its NK Cell Therapy In Lymphoma Settings
Affimed N.V. (NASDAQ: AFMD)  
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Rise and shine, investor! It's time to start off another week of trading with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Outlook For Affimed
Affimed (NASDAQ:AFMD) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Affimed will report... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
20 Stocks Moving in Thursday's Pre-Market Session
Gainers Mercurity Fintech Holding Inc. (NYSE: MFH) rose 91% to $4.03 in pre-market trading. Energy Services of America Corporation (NASDAQ: ESOA) shares rose 40% to $4.62 in pre-... 
Via Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets. 
Via Benzinga
3 Best Biopharma Stocks to Buy During This Industrywide Fire Sale
Affimed, Amgen, and Bristol Myers Squibb are too cheap to ignore right now. 
Via The Motley Fool
Exposures COVID-19
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Affimed NV (NASDAQ:AFMD) has announced 
Via Benzinga
Why Affimed Stock Is On Fire Today
The biotech's early-stage trial results are turning heads on Wall Street today. 
Via The Motley Fool
Why Affirmed Stock Was Up More Than 12% Wednesday
Positive trial results regarding the company's pipeline are buoying the stock's price. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Falls 200 Points; Rockwell Medical Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded down 0.58% to 35,930.89 while the NASDAQ fell 0.27% to 15,930.79. The S&P also fell, dropping 0.23% to 4,690.24. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Affimed NV (AFMD) Q3 2021 Earnings Call Transcript
AFMD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2021
Upgrades For Coterra Energy Inc (NYSE:CTRA), Piper... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
Affimed NV (NasdaqGM:AFMD) (AFMD) Q2 2021 Earnings Call Transcript
AFMD earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Earnings Scheduled For September 8, 2021
Companies Reporting Before The Bell • Nanobiotix (NASDAQ:NBTX) is likely to report earnings for its first quarter. • Waterdrop (NYSE:WDH) is expected to report... 
Via Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.